C Reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: Four year results from the GENERATION study

Heart

Volumn 90, Issue 4, 2004, Pages 419-424

  Zairis, M N ^a,b   Ambrose, J A ^c   Lyras, A G ^b   Thoma, M A ^b   Psarogianni, P K ^b   Psaltiras, G P ^b   Kardoulas, A D ^b   Bibis, G P ^b   Pissimissis, E G ^b   Batika, P C ^b   DeVoe, M C ^c   Prekates, A A ^b   Foussas, S G ^b  

^a Tzanio Hospital ^*  (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; UNSTABLE ANGINA PECTORIS;

EID: 12144291035     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.016337     Document Type: Article

References (30)

1. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
2. Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-46.
3. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;28:974-5.
4. de Winter RJ, Heyde GS, Koch KT, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002;23:960-6.
5. Klatsky AL, Armstrong MA, Friedman GD. Alcohol and mortality. Ann Intern Med 1992;117:646-54.
6. Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease: a review. Medicine (Baltimore) 1986;65:242-67.
7. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73.
8. Colditz GA, Branch LG, Lipnick RJ, et al. Moderate alcohol and decreased cardiovascular mortality in an elderly cohort. Am Heart J 1985;109:886-9.
9. Bradley KA, Donovan DM, Larson EB. How much is too much? Advising patients about safe levels of alcohol consumption. Arch Intern Med 1993;153:2734-40.
10. Thun JT, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;337:1705-14.
11. Shaper AG, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining the U-shaped curve. Lancet 1988;ii:1267-73.
12. Gaziano JM, Gaziano TA, Glynn RJ, et al. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. J Am Coll Cardiol 2000;35:96-105.
13. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfroctions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34.
14. Moore RD, Smith CR, Kwiterovich PO, et al. Effect of low-dose alcohol use versus abstention on apolipoproteins A-I and B. Am J Med 1988;84:884-90.
15. Suh I, Shaten BJ, Cutler JA, et al. Alcohol use and mortality from coronary heart disease: the role of high-density lipoprotein cholesterol. Ann Intern Med 1992;116:881-7.
16. Hulley SB, Gordon S. Alcohol and high-density lipoprotein cholesterol: causal inference from diverse study designs. Circulation 1981 ;64(suppl III):III-57-63.
17. Ridker PM, Vaughan DE, Stampfer MJ, et al. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 1994;272:929-33.
18. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-6.
19. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: trie global evaluation of new events and restenosis after stent implantation study. J Am Coll Cardiol 2002;40:1375-82.
20. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
21. Biasucci LM, Liuzzo G, Colizzi C, et al. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001;2:164-71.
22. Shaper AG, Wannamethee SG. Alcohol intake and mortality in middle aged men with diagnosed coronary heart disease. Heart 2000;83:394-9.
23. Muntwvler J, Hennekens CH, Buring JE, et al. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet 1998;352:1882-5.
24. de Lorgeril M, Salen P, Martin JL, et al. Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 2002;106:1465-9.
25. Gordon T, Ernst N, Fisher M, et al. Alcohol and high-density lipoprotein cholesterol. Circulation 1981;64:III 63-7.
26. Pearson AT. Alcohol and heart disease. Circulation 1996;94:3023-25.
27. van der Gaag MS, van den Berg R, van den Berg H, et al. Moderate consumption of beer, red wine and spirits has counteracting effects on plasma antioxidants in middle-aged men. Eur J Clin Nutr 2000;54:586-91.
28. Rimm EB, Klatsky A, Grobbee D, et al. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ 1996;312:731-6.
29. Iijima K, Yoshizumi M, Ouchi Y. Effect of red wine polyphenols on vascular smooth muscle cell function - molecular mechanism of the "French paradox". Mech Ageing 2002;123:1033-9.
30. Imhof A, Froehlich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;357:763-7.